Cognition Therapeutics Inc (CGTX NASDAQ) stock market data APIs
$1.0145
0.01(1%)
as of September 1, 2026
Try our APIs with
free plan!
Cognition Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Prev. Close
1.0145
Open
1.023
High
1.023
Low
0.9905
52 wk Range
0.55-2.67
Market Cap
96 045 K
Shares Outstanding
95 094 K
EPS
-0.04
Beta
1.776
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cognition Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cognition Therapeutics Inc data using free add-ons & libraries
Get Cognition Therapeutics Inc Fundamental Data
Cognition Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -36 551 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Cognition Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-06
- EPS/Forecast: -0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cognition Therapeutics Inc News
New
Cognition Therapeutics Q2 Net Loss Narrows; Plans Phase 3 DLB Study Of Zervimesine In Mid 2027
(RTTNews) - Cognition Therapeutics, Inc. (CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, reported second quarter results reflecting a narrowed ne...
Dementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsight
The dementia-related psychosis market is anticipated to increase during the forecast period (2026–2036), owing to the rising burden of dementia, the emergence of novel therapies such as ACP-204 (Rem...
Cognition Seures FDA Alignment For Pivotal Phase 3 Trial Of Zervimesine In DLB Psychosis
(RTTNews) - Cognition Therapeutics, Inc. (CGTX) announced that it has reached key alignment with the U.S. FDA on the design of its pivotal Phase 3 study evaluating Zervimesine for psychosis associated...
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, N.Y., June 24, 2026 (...
Get Cognition Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
